The said research alliance aims to further develop iCardiac's COMPAS platform and advanced ECG markers for use in the safety testing of in-development and on-market drugs. The terms of agreement include the following:The COMPAS technology was developed at the University of Rochester within its Heart Research Follow-Up Program (HRFUP), a premier group of electrocardiology researchers focused on the ventricular repolarization process of the heart, and exclusively licensed to iCardiac.
- The two companies will collaborate on a research program comprised of a series of studies, including retrospective and prospective ECG data analyses.
- iCardiac will receive an equity investment and technology license payment, plus research and development funding over the term of the alliance.
- iCardiac will retain commercial rights to the validated technology platform and new biomarkers for future application in cardiac safety clinical trials and technologies.
iCardiac Technologies is a privately-held clinical technology company focused on the development of advanced ECG-based cardiac safety biomarkers.
The alliance with Pfizer aims to improve the precision, increase the speed and reduce the costs of cardiac safety clinical trials.
Find more details from the press release.
Comment Preview